Loading
A phase 3 trial of Pemetrexed, Carboplatin, Cisplatin in mesothelioma, run by AstraZeneca, active and no longer recruiting.
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma is a phase 3 interventional study registered as NCT06097728 by AstraZeneca, with 863 participants enrolled, started 2023-11-09 and due to reach its primary completion in 2028-11-16. Interventions recorded: Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab. Conditions listed: Unresectable Pleural Mesothelioma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Nivolumab, Platinum agents, Cisplatin.
Shares Ipilimumab, Pemetrexed, Nivolumab, Cisplatin.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.
Shares Pemetrexed, AstraZeneca, Platinum agents, Cisplatin.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.
Shares Pemetrexed, Platinum agents, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/